Arizona State Retirement System Has $2.47 Million Stake in United Therapeutics Corporation (UTHR)
Arizona State Retirement System boosted its position in United Therapeutics Corporation (NASDAQ:UTHR) by 1.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 19,000 shares of the biotechnology company’s stock after buying an additional 300 shares during the period. Arizona State Retirement System’s holdings in United Therapeutics Corporation were worth $2,465,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the company. Focused Wealth Management Inc increased its stake in United Therapeutics Corporation by 17.5% in the first quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock worth $127,000 after buying an additional 140 shares during the last quarter. Advisory Services Network LLC bought a new stake in United Therapeutics Corporation during the first quarter worth $147,000. Daiwa Securities Group Inc. increased its stake in United Therapeutics Corporation by 17.4% in the first quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock worth $183,000 after buying an additional 200 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in United Therapeutics Corporation during the first quarter worth $204,000. Finally, Eagle Global Advisors LLC bought a new stake in United Therapeutics Corporation during the second quarter worth $206,000.
United Therapeutics Corporation (NASDAQ UTHR) opened at 129.10 on Friday. United Therapeutics Corporation has a one year low of $110.90 and a one year high of $169.89. The company has a 50-day moving average of $130.38 and a 200-day moving average of $134.34. The company has a market cap of $5.61 billion, a price-to-earnings ratio of 14.97 and a beta of 1.51.
United Therapeutics Corporation (NASDAQ:UTHR) last issued its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by $4.86. The firm had revenue of $444.60 million during the quarter, compared to analysts’ expectations of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company earned $4.42 EPS. Equities research analysts expect that United Therapeutics Corporation will post $10.09 EPS for the current fiscal year.
United Therapeutics Corporation declared that its Board of Directors has approved a share repurchase plan on Thursday, April 27th that allows the company to buyback $250.00 million in shares. This buyback authorization allows the biotechnology company to buy up to 4.6% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/08/20/arizona-state-retirement-system-has-2-47-million-stake-in-united-therapeutics-corporation-uthr.html.
A number of equities research analysts have recently weighed in on UTHR shares. ValuEngine downgraded shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 2nd. BidaskClub upgraded shares of United Therapeutics Corporation from a “sell” rating to a “hold” rating in a research note on Friday, June 16th. Jefferies Group LLC restated a “sell” rating and issued a $105.00 price target on shares of United Therapeutics Corporation in a research note on Thursday, June 8th. UBS AG restated a “sell” rating and issued a $106.00 price target on shares of United Therapeutics Corporation in a research note on Thursday, July 6th. Finally, Zacks Investment Research downgraded shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Six research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company’s stock. United Therapeutics Corporation currently has an average rating of “Hold” and an average target price of $134.50.
In other news, Director Raymond Dwek sold 3,490 shares of the stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $131.71, for a total transaction of $459,667.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 2,176 shares of the stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $127.11, for a total value of $276,591.36. Following the sale, the chief executive officer now directly owns 3,245 shares of the company’s stock, valued at approximately $412,471.95. The disclosure for this sale can be found here. In the last three months, insiders have sold 24,649 shares of company stock valued at $3,192,423. Insiders own 7.80% of the company’s stock.
United Therapeutics Corporation Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.